
VEGF-ADC-01（DAR4）
OD450 nm
浓度（ ng/mL）
人/食蟹猴 VEGF165
大鼠 VEGF164
小鼠 VEGF164

图 1a



抗VEGF抗体
OD450 nm
浓度（ ng/mL）
人/食蟹猴 VEGF165
大鼠 VEGF164
小鼠 VEGF164

图 1b



OD450 nm
VEGF-ADC-01(DAR4)
抗VEGF抗体
VEGFA
VEGF-B
VEGF-C
VEGF-D
PLGF-2

图 2



***
***
****
***
ns
No.of meshes
40
30
20
10
0
VEGF
VEGF+Avastin
VEGF+12 uM毒素
VEGF+3 uM抗VEGF抗体
VEGF+3 uM VEGF-ADC-01(DAR4)

图 3a



***
***
****
***
ns
No.of master junction
80
60
40
20
0
VEGF
VEGF+Avastin
VEGF+12 uM毒素
VEGF+3 uM抗VEGF抗体
VEGF+3 uM VEGF-ADC-01(DAR4)

图 3b



100 ng/mL VEGF
100 ng/mL VEGF+3.35μM Avastin
100 ng/mL VEGF+12 μM 毒素
100 ng/mL VEGF+3 μM 抗 VEGF 抗体
100 ng/mL VEGF+3 μM VEGF-ADC-01（DAR4）

图 3c



SW480 Tumor Volume
Tumor Volume (mean mm3 ± SEM)
4000
3000
2000
1000
0
0
5
10
15
20
25
30
Treatment days
Vehicle (Saline)
抗VEGF抗体, 5mg/kg
IgG1-ADC（DAR8）, 10mg/kg
VEGF-ADC-01（DAR8）, 5mg/kg
VEGF-ADC-01(DAR8), 10mg/kg
VEGF-ADC-01(DAR4), 10mg/kg
VEGF-ADC-01(DAR4), 20mg/kg
Administration

图 4



SW480 Body Weight
Body Weight (mean g ± SEM)
30
28
26
24
22
20
18
0
5
10
15
20
25
30
Treatment days
Vehicle (Saline)
抗VEGF抗体, 5mg/kg
IgG1-ADC（DAR8）, 10mg/kg
VEGF-ADC-01（DAR8）, 5mg/kg
VEGF-ADC-01（DAR8）, 10mg/kg
VEGF-ADC-01（DAR4）, 10mg/kg
VEGF-ADC-01（DAR4）, 20mg/kg
Administration

图 5



NCI-H358 CDX 模型-肺癌
肿瘤体积
(mean mm3±SEM)
1200
900
600
300
0
0
5
10
15
20
25
分组后天数
生理盐水
抗VEGF抗体, 3mg/kg
毒素, 0.07mg/kg
IgG1-ADC(DAR4), 3mg/kg
VEGF-ADC-01(DAR4), 0.5mg/kg
VEGF-ADC-01(DAR4), 1mg/kg
VEGF-ADC-01(DAR4), 3mg/kg
给药

图 6



NCI-H358模型小鼠体重
体重 (g)
28
26
24
22
20
18
0
5
10
15
20
25
分组后天数
生理盐水
抗VEGF抗体, 3mg/kg
毒素, 0.07mg/kg
IgG1-ADC(DAR4), 3mg/kg
VEGF-ADC-01(DAR4), 0.5mg/kg
VEGF-ADC-01(DAR4), 1mg/kg
VEGF-ADC-01(DAR4), 3mg/kg
给药

图 7



Tumor Volume
Tumor Volume (mean mm3 ±SEM)
1500
1000
500
0
0
5
10
15
20
25
Treatment days
Vehicle
抗VEGF抗体, 5mg/kg
IgG1-ADC(DAR4), 5mg//kg
VEGF-ADC-01(DAR4), 5mg/kg
Administration

图 8



Body Weight (g)
30
25
20
15
0
5
10
15
20
25
Days after treatment
Vehicle
抗VEGF抗体, 5mg/kg
IgG1-ADC(DAR4), 5mg/kg
VEGF-ADC-01(DAR4), 5 mg/kg
Administration

图 9